Fermented and Fiber-rich Food (FeFiFo) Study
Primary Purpose
Metabolic Syndrome, Microbiome, Immune Function
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Dietary Fiber
Fermented Foods
Sponsored by
About this trial
This is an interventional prevention trial for Metabolic Syndrome
Eligibility Criteria
Inclusion Criteria:
- 18 and older, both genders, all ethnic backgrounds
- Healthy subjects willing and able to provide blood, as well as stool specimens
- Able to provide signed and dated informed consent.
Exclusion Criteria:
- Body Mass Index higher than 40.
- Vital signs outside of acceptable range at Screening Visit, i.e., blood pressure greater than 160/100, oral temperature greater than 100 degrees F, pulse greater than 100.
Use of any of the following drugs within the last 6 months:
- systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular, or oral);
- oral, intravenous, intramuscular, nasal or inhaled corticosteroids;
- cytokines;
- methotrexate or immunosuppressive cytotoxic agents;
- large doses of commercial probiotics consumed (greater than or equal to 10e8 cfu or organisms per day) - includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component.
- consumption of > 20 g fiber/day and > 7 servings of fermented foods per week.
- Acute disease at the time of enrollment (defer sampling until subject recovers). Acute disease is defined as the presence of a moderate or severe illness with or without fever.
- Chronic, clinically significant (unresolved, requiring on-going medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality, as determined by medical history or physical examination.
- History of cancer except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision.
- Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet.
- Recent history of chronic alcohol consumption defined as more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day.
- Positive test for HIV, HBV or HCV.
- Any confirmed or suspected condition/state of immunosuppression or immunodeficiency ( primary or acquired) including HIV infection.
- Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time.
History of active uncontrolled gastrointestinal disorders or diseases including:
- inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis;
- irritable bowel syndrome (IBS) (moderate-severe);
- persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated);
- chronic constipation.
Female who is pregnant or lactating.
Sites / Locations
- Stanford University School of Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Fiber Group
Fermented Foods Group
Arm Description
Participants are asked to increase their usual dietary fiber intake by 20 grams/day.
Participants are asked to consume 6 servings of fermented foods per day.
Outcomes
Primary Outcome Measures
Immune profile: Cytokine Response Score (CRS)
Change from baseline in CRS at 10 weeks
Secondary Outcome Measures
Microbiota metabolites: short-chain fatty acids (SCFA)
Change from baseline in short-chain fatty acids (SCFA) at 10 weeks.
Microbiota composition
Change from baseline in 16S rRNA enumeration at 10 weeks, determined using Illumina-based sequencing.
Full Information
NCT ID
NCT03275662
First Posted
September 6, 2017
Last Updated
February 22, 2023
Sponsor
Stanford University
1. Study Identification
Unique Protocol Identification Number
NCT03275662
Brief Title
Fermented and Fiber-rich Food (FeFiFo) Study
Official Title
Microbiota-targeted Dietary Strategies to Reduce Inflammatory Markers of Americans: High Fiber vs Fermented Food
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
August 29, 2016 (Actual)
Primary Completion Date
June 2, 2017 (Actual)
Study Completion Date
June 2, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stanford University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The primary objective is to contrast the degree to which increased consumption of dietary fiber vs. fermented food can decrease inflammation, increase microbiota diversity and can impact microbiota production of short-chain fatty acids (SCFA), potential normalizers of metabolic and immune dysfunction, in obese and non-obese adults.
Detailed Description
The gut microbiota is central to human health, and the modern, industrialized gut microbiota has been linked to numerous chronic diseases that are driven by inflammation. It is likely dietary changes in the last half-century consistent with adoption of the Western diet have had an adverse impact on the gut microbiota. A critically important next step in this field of research is to identify how different dietary interventions can potentially restore healthy features of the gut microbiota in alignment with the optimization of human health. Dietary interventions that target the microbiota and reduce inflammation may reverse or prevent chronic diseases including obesity, metabolic syndrome, and inflammatory bowel disease. This study is designed to elicit and contrast inflammatory markers in blood with the amount of increase in microbiota diversity and related metabolic output achievable by two dietary approaches commonly available to the general population. The results could contribute to dietary recommendations for reversing the chronic disease epidemics of Westernization.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, Microbiome, Immune Function, Inflammation
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
37 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fiber Group
Arm Type
Experimental
Arm Description
Participants are asked to increase their usual dietary fiber intake by 20 grams/day.
Arm Title
Fermented Foods Group
Arm Type
Experimental
Arm Description
Participants are asked to consume 6 servings of fermented foods per day.
Intervention Type
Behavioral
Intervention Name(s)
Dietary Fiber
Intervention Type
Behavioral
Intervention Name(s)
Fermented Foods
Primary Outcome Measure Information:
Title
Immune profile: Cytokine Response Score (CRS)
Description
Change from baseline in CRS at 10 weeks
Time Frame
Baseline and 10 weeks
Secondary Outcome Measure Information:
Title
Microbiota metabolites: short-chain fatty acids (SCFA)
Description
Change from baseline in short-chain fatty acids (SCFA) at 10 weeks.
Time Frame
Baseline and 10 weeks
Title
Microbiota composition
Description
Change from baseline in 16S rRNA enumeration at 10 weeks, determined using Illumina-based sequencing.
Time Frame
Baseline and 10 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
18 and older, both genders, all ethnic backgrounds
Healthy subjects willing and able to provide blood, as well as stool specimens
Able to provide signed and dated informed consent.
Exclusion Criteria:
Body Mass Index higher than 40.
Vital signs outside of acceptable range at Screening Visit, i.e., blood pressure greater than 160/100, oral temperature greater than 100 degrees F, pulse greater than 100.
Use of any of the following drugs within the last 6 months:
systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular, or oral);
oral, intravenous, intramuscular, nasal or inhaled corticosteroids;
cytokines;
methotrexate or immunosuppressive cytotoxic agents;
large doses of commercial probiotics consumed (greater than or equal to 10e8 cfu or organisms per day) - includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component.
consumption of > 20 g fiber/day and > 7 servings of fermented foods per week.
Acute disease at the time of enrollment (defer sampling until subject recovers). Acute disease is defined as the presence of a moderate or severe illness with or without fever.
Chronic, clinically significant (unresolved, requiring on-going medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality, as determined by medical history or physical examination.
History of cancer except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision.
Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet.
Recent history of chronic alcohol consumption defined as more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day.
Positive test for HIV, HBV or HCV.
Any confirmed or suspected condition/state of immunosuppression or immunodeficiency ( primary or acquired) including HIV infection.
Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time.
History of active uncontrolled gastrointestinal disorders or diseases including:
inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis;
irritable bowel syndrome (IBS) (moderate-severe);
persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated);
chronic constipation.
Female who is pregnant or lactating.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Justin L Sonnenburg, PhD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christopher D Gardner, PhD
Organizational Affiliation
Stanford University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Stanford University School of Medicine
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
34256014
Citation
Wastyk HC, Fragiadakis GK, Perelman D, Dahan D, Merrill BD, Yu FB, Topf M, Gonzalez CG, Van Treuren W, Han S, Robinson JL, Elias JE, Sonnenburg ED, Gardner CD, Sonnenburg JL. Gut-microbiota-targeted diets modulate human immune status. Cell. 2021 Aug 5;184(16):4137-4153.e14. doi: 10.1016/j.cell.2021.06.019. Epub 2021 Jul 12.
Results Reference
background
Links:
URL
https://med.stanford.edu/nutrition/research/completed-studies/fefifo.html
Description
Study description and results summary
Learn more about this trial
Fermented and Fiber-rich Food (FeFiFo) Study
We'll reach out to this number within 24 hrs